SUMO1

Small ubiquitin-related modifier 1 · P63165 · SUMO1 on Sugi Atlas →

9,440 patent compounds predicted against SUMO1, 5,595 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3958375 SCHEMBL3958375 1.00 7/20
SCHEMBL2622737 SCHEMBL2622737 0.56 7/20
SCHEMBL1712890 SCHEMBL1712890 0.58 6/20
SCHEMBL3915968 SCHEMBL3915968 0.71 5/20
SCHEMBL110923 SCHEMBL110923 0.60 5/20
SCHEMBL110924 SCHEMBL110924 0.60 5/20
SCHEMBL1436156 SCHEMBL1436156 0.60 5/20
SCHEMBL1436155 SCHEMBL1436155 0.59 5/20
SCHEMBL3487054 SCHEMBL3487054 0.57 5/20
SCHEMBL414245 SCHEMBL414245 0.52 5/20
SCHEMBL3714721 SCHEMBL3714721 0.51 5/20
SCHEMBL3714723 SCHEMBL3714723 0.51 5/20
SCHEMBL3433588 SCHEMBL3433588 0.44 5/20
SCHEMBL3423417 SCHEMBL3423417 0.41 5/20
SCHEMBL3427611 SCHEMBL3427611 0.38 5/20
SCHEMBL2592201 SCHEMBL2592201 1.00 4/20
SCHEMBL2592202 SCHEMBL2592202 1.00 4/20
SCHEMBL2587118 SCHEMBL2587118 0.73 4/20
SCHEMBL2593909 SCHEMBL2593909 0.73 4/20
SCHEMBL2587651 SCHEMBL2587651 0.72 4/20

Clinical trials — most relevant to SUMO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Oral Nitrite for Older Heart Failure Patients PHASE2COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level nanENROLLING_BY_INVITATION
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults nanNOT_YET_RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Genetic Analysis to Predict the Development of Paget's Disease nanACTIVE_NOT_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SUMO1 binder may also engage these)

ProteinNameSimilarity
P63166 1.000 P63166 →
Q5I0H3 1.000 Q5I0H3 →
A7WLH8 1.000 A7WLH8 →
Q5E9D1 1.000 Q5E9D1 →
Q5R6J4 1.000 Q5R6J4 →
Q2EF74 1.000 Q2EF74 →
Q8QGH2 1.000 Q8QGH2 →
Q6DEP7 1.000 Q6DEP7 →
Q9MZD5 1.000 Q9MZD5 →
Q9PT08 1.000 Q9PT08 →
Q5EAX4 1.000 Q5EAX4 →
O57686 1.000 O57686 →
Q7SZR5 1.000 Q7SZR5 →
Q9FLP6 0.983 Q9FLP6 →
P55853 0.980 P55853 →
G2XKQ0 0.978 G2XKQ0 →
P55852 0.975 P55852 →
P55857 0.974 P55857 →
P61959 0.966 P61959 →
Q2PFW2 0.966 Q2PFW2 →
SUMO3 Small ubiquitin-related modifier 3 (SUMO-3) ( 0.966 landscape →
Q6LDZ8 0.965 Q6LDZ8 →
P61957 0.965 P61957 →
Q6DI05 0.965 Q6DI05 →
Q6DHL4 0.964 Q6DHL4 →
Q6NV25 0.964 Q6NV25 →
Q6GPW2 0.964 Q6GPW2 →
Q5ZHQ1 0.963 Q5ZHQ1 →
Q12306 0.961 Q12306 →
Q28H04 0.961 Q28H04 →